

27 Oct 2020 | News

# QUOTED. 27 October 2020. Michael Mussallem.

by

TAVR procedure volumes have returned to or exceeded pre-pandemic levels in most locations, Edwards LifeSciences CEO Michael Mussallem said during the company's 21 October earnings call.

“Our observations indicate that most hospitals globally have determined that they can safely treat their [aortic stenosis] patients in need and at the same time, care for COVID patients. Strong evidence indicates that TAVR is a proven therapy with excellent outcomes. It offers efficient use of hospital resources and can benefit many more patients whose structural heart disease is deadly and undertreated today.”— Michael Mussallem, CEO, Edwards LifeSciences

- Find out more: [Edwards Returns To Growth In The Third Quarter](#)

[Click here](#) for a free trial of *Medtech Insight*